rifampin has been researched along with Oral-Ulcer* in 3 studies
3 other study(ies) available for rifampin and Oral-Ulcer
| Article | Year |
|---|---|
Tuberculosis cutis orificialis in an immunocompetent patient.
Topics: Antibiotics, Antitubercular; Diagnosis, Differential; Drug Combinations; Ethambutol; Female; Humans; Middle Aged; Mycobacterium tuberculosis; Oral Ulcer; Pyrazinamide; Rifampin; Tuberculosis, Oral | 2015 |
Palatal ulceration as the first sign of pulmonary tuberculosis: a case report.
Tuberculosis (TB) is one of the leading casues of morbidity and death in a number of countries worldwide. A healthy 42-year-old patient presented with a chronic palatal ulcer that was not responsive to routine antibiotic treatment. A biopsy and further systemic investigation revealed a diagnosis of TB. An eight-month extended course of oral rifampin and isoniazid was instituted successfully resulting in complete resolution of symptoms. It is important that clinicians be aware that chronic oral ulcerations may be the first sign of systemic disease. A biopsy should therefore be mandatory for any chronic oral ulcer not responsive to conventional treatment. Topics: Adult; Antitubercular Agents; Chronic Disease; Humans; Isoniazid; Male; Mouth Mucosa; Mycobacterium tuberculosis; Oral Ulcer; Rifampin; Treatment Outcome; Tuberculosis, Oral; Tuberculosis, Pulmonary | 2012 |
Oral tuberculosis following autologous bone marrow transplantation for Hodgkin's disease with interleukin-2 and alpha-interferon immunotherapy.
A patient with Hodgkin's disease (HD) underwent autologous bone marrow transplantation (ABMT). Six months later while receiving interleukin (IL)-2 and alpha-interferon immunotherapy, he developed a painful lesion in his oral cavity with a fistula in the buccal area. Excision biopsy disclosed necrotizing granulomatous inflammation with acid-fast bacillus. The patient received a 9-month course of isoniazide, rifampin and pyrazinamide, and recovered. The possible pathophysiological mechanism is discussed. Topics: Adjuvants, Immunologic; Adult; Anti-Bacterial Agents; Antitubercular Agents; Bone Marrow Transplantation; Combined Modality Therapy; Disease Susceptibility; Drug Therapy, Combination; Fistula; Hodgkin Disease; Humans; Immunocompromised Host; Interferon-alpha; Interleukin-2; Isoniazid; Male; Opportunistic Infections; Oral Ulcer; Pyrazinamide; Recombinant Proteins; Rifampin; Risk Factors; Transplantation Conditioning; Transplantation, Autologous; Tuberculosis, Oral | 1996 |